June 19, 2020
1 min watch
Save
VIDEO: Tiragolumab plus atezolizumab confers benefit for certain patients with NSCLC
In this video, Julia K. Rotow, MD, medical oncologist at Dana-Farber Cancer Institute, shared her thoughts on data from the CITYSCAPE trial presented during the ASCO20 Virtual Scientific Program.
The CITYSCAPE trial compared the anti-TIGIT antibody tiragolumab (Roche) plus atezolizumab (Tecentriq, Genentech/Roche) with placebo plus atezolizumab as a first-line treatment for patients with PD-L1-selected non-small cell lung cancer.
“It’s really exciting to see a novel immune checkpoint inhibitor showing clinical benefit for patients,” she said.
Rotow underscored that the data was “primarily driven” by the objective response rate and PFS of patients with high PD-L1 expression.
Reference:
- Rodriguez-Abreu D, et al. Abstract 9503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Rotow reports a consultant/advisory role with AstraZeneca, travel, accommodations and expenses from Array and Eli Lilly, and honoraria from Takeda.
Read more about